| Code | CSB-RA020977MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Aselizumab, targeting SELL (Selectin L, also known as L-selectin or CD62L). SELL is a cell adhesion molecule expressed on leukocytes that plays a critical role in lymphocyte homing and trafficking by mediating the initial tethering and rolling of white blood cells along the vascular endothelium. This selectin family member is essential for immune cell migration to lymph nodes and sites of inflammation through interactions with its ligands on high endothelial venules. Dysregulated SELL expression and function are implicated in various pathological conditions, including inflammatory diseases, immune disorders, and certain malignancies where aberrant leukocyte trafficking contributes to disease progression.
Aselizumab, the reference antibody, was originally investigated for its ability to modulate leukocyte adhesion and migration in transplant rejection and inflammatory conditions. This biosimilar provides researchers with a valuable tool for investigating SELL-mediated cellular adhesion mechanisms, studying immune cell trafficking patterns, and exploring potential therapeutic interventions targeting leukocyte migration in inflammation and immune-related disorders.
There are currently no reviews for this product.